Nanoliposomal Encapsulation and Purification of Angiotensin-Converting Enzyme Inhibitor Peptides from Ulva rigida.

Şensu, Eda et al.·ACS omega·2025·Preliminary Evidencelaboratory study
RPEP-14681Laboratory studyPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
laboratory study
Evidence
Preliminary Evidence
Sample
N=Not applicable (laboratory study)
Participants
Ulva rigida green seaweed protein hydrolysates

What This Study Found

ACE-inhibitory peptides purified from green seaweed (Ulva rigida) and encapsulated in chitosan-coated nanoliposomes achieved 92% encapsulation efficiency and retained 37.5% of their blood pressure-lowering activity after encapsulation.

Key Numbers

Ulva rigida hydrolyzed with pepsin then trypsin. Peptides <3 kDa showed strongest ACE inhibition. Identified by mass spectrometry and in silico analysis. Nanoliposome encapsulation efficiency: 92.0 ± 4.5%. ACE-inhibitory activity retained: 37.5% after encapsulation.

How They Did This

Enzymatic hydrolysis of U. rigida protein, ultrafiltration by molecular weight, ion exchange chromatography, mass spectrometry and in silico peptide identification, nanoliposome formulation with chitosan coating, physical characterization (zeta potential, PDI, size, DSC, SEM, FT-IR), and ACE inhibition assay.

Why This Research Matters

Natural peptides that lower blood pressure degrade quickly. Nanoliposome encapsulation could make them stable enough for use as functional food ingredients or supplements.

What This Study Doesn't Tell Us

In vitro only. Significant activity loss after encapsulation (62.5%). Oral bioavailability and in vivo antihypertensive effect not tested. Seaweed peptide yields may vary by batch.

Trust & Context

Original Title:
Nanoliposomal Encapsulation and Purification of Angiotensin-Converting Enzyme Inhibitor Peptides from Ulva rigida.
Published In:
ACS omega, 10(21), 21609-21620 (2025)
Database ID:
RPEP-14681

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-14681·https://rethinkpeptides.com/research/RPEP-14681

APA

Şensu, Eda; Koku, Harun; Demircan, Evren; Şişman, Sebahat; Gülseren, İbrahim; Karaduman, Tuğçe; Çakır, Bilal; Okudan, Emine Şükran; Duruksu, Gökhan; Özçelik, Beraat; Yücetepe, Aysun. (2025). Nanoliposomal Encapsulation and Purification of Angiotensin-Converting Enzyme Inhibitor Peptides from Ulva rigida.. ACS omega, 10(21), 21609-21620. https://doi.org/10.1021/acsomega.5c00780

MLA

Şensu, Eda, et al. "Nanoliposomal Encapsulation and Purification of Angiotensin-Converting Enzyme Inhibitor Peptides from Ulva rigida.." ACS omega, 2025. https://doi.org/10.1021/acsomega.5c00780

RethinkPeptides

RethinkPeptides Research Database. "Nanoliposomal Encapsulation and Purification of Angiotensin-..." RPEP-14681. Retrieved from https://rethinkpeptides.com/research/sensu-2025-nanoliposomal-encapsulation-and-purification

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.